Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT as Adjunct to Keytruda in Metastatic Mesothelioma
NCT04056026Phase 1Completed
- Sponsor
- ProgenaBiome
- Start
- Sep 2018
- Primary completion
- Dec 2018
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fecal microbiome transplant in mesothelioma, sponsored by ProgenaBiome. Primary endpoint: Progression free survival at 5 years. Started Sep 2018; status: completed.
02
Drugs
fecal microbiome transplant
03
Conditions
mesothelioma
Beyond the preview
Go deeper on NCT04056026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04056026.